A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy

Patricia L. Judson, Amy L. Jonson, Pamela J. Paley, Robin L. Bliss, Karuna P. Murray, Levi S. Downs, Matthew P. Boente, Peter A. Argenta, Linda F. Carson

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Based on the reduced morbidity seen in our retrospective study, we undertook a prospective, randomized trial to determine whether transposition of the sartorius muscle improves post-operative morbidity in women with squamous cell carcinoma of the vulva undergoing inguinal-femoral lymphadenectomy. Patients with squamous carcinoma of the vulva requiring inguinal-femoral lymphadenectomy were randomized to undergo sartorius transposition or not. All patients received perioperative antibiotics, DVT prophylaxis, and closed suction surgical site drainage. Outcomes assessed include wound cellulitis, wound breakdown, lymphocyst formation, lymphedema, and/or rehospitalization. Cohorts were compared using Fisher's exact test. Baseline characteristics were compared using Student's t test or Fischer's exact test as appropriate. Logistic regression was used to assess the impact of sartorius transposition, after adjusting for other factors. From June 1996 to December 2002, 61 patients underwent 99 inguinal-femoral lymphadenectomies, 28 with sartorius transposition, and 33 without. The mean (SD) age for controls and patients undergoing sartorius transposition was 63.5 (15.2) and 73.8 (13.7) years, respectively (P < 0.05). There were no statistically significant differences in BSA, tobacco use, co-morbid medical conditions, past surgical history, medication use, size of incision, duration of surgery, number of positive lymph nodes, pathologic stage, pathologic grade, pre- or postoperative hemoglobin, or length of hospitalization. There were no statistically significant differences in the incidence of wound cellulitis, wound breakdown, lymphedema, or rehospitalization. The incidence of lymphocyst formation was increased in the sartorius transposition group. After adjusting for age, however, the groups appeared similar. Sartorius transposition after inguinal-femoral lymphadenectomy does not reduce postoperative wound morbidity.

Original languageEnglish (US)
Pages (from-to)226-230
Number of pages5
JournalGynecologic Oncology
Volume95
Issue number1
DOIs
StatePublished - Oct 1 2004

Fingerprint

Groin
Thigh
Lymph Node Excision
Prospective Studies
Wounds and Injuries
Cellulitis
Vulva
Lymphedema
Morbidity
Squamous Cell Carcinoma
Antibiotic Prophylaxis
Incidence
Suction
Tobacco Use
Drainage
Hemoglobins
Hospitalization
Retrospective Studies
Age Groups
Logistic Models

Keywords

  • Inguinal-femoral
  • Lymphadenectomy
  • Sartorius transposition

Cite this

Judson, P. L., Jonson, A. L., Paley, P. J., Bliss, R. L., Murray, K. P., Downs, L. S., ... Carson, L. F. (2004). A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. Gynecologic Oncology, 95(1), 226-230. https://doi.org/10.1016/j.ygyno.2004.07.022

A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. / Judson, Patricia L.; Jonson, Amy L.; Paley, Pamela J.; Bliss, Robin L.; Murray, Karuna P.; Downs, Levi S.; Boente, Matthew P.; Argenta, Peter A.; Carson, Linda F.

In: Gynecologic Oncology, Vol. 95, No. 1, 01.10.2004, p. 226-230.

Research output: Contribution to journalArticle

Judson, PL, Jonson, AL, Paley, PJ, Bliss, RL, Murray, KP, Downs, LS, Boente, MP, Argenta, PA & Carson, LF 2004, 'A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy', Gynecologic Oncology, vol. 95, no. 1, pp. 226-230. https://doi.org/10.1016/j.ygyno.2004.07.022
Judson, Patricia L. ; Jonson, Amy L. ; Paley, Pamela J. ; Bliss, Robin L. ; Murray, Karuna P. ; Downs, Levi S. ; Boente, Matthew P. ; Argenta, Peter A. ; Carson, Linda F. / A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. In: Gynecologic Oncology. 2004 ; Vol. 95, No. 1. pp. 226-230.
@article{af7aaaaf410f4a14ad8ad0c1ab922fb3,
title = "A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy",
abstract = "Based on the reduced morbidity seen in our retrospective study, we undertook a prospective, randomized trial to determine whether transposition of the sartorius muscle improves post-operative morbidity in women with squamous cell carcinoma of the vulva undergoing inguinal-femoral lymphadenectomy. Patients with squamous carcinoma of the vulva requiring inguinal-femoral lymphadenectomy were randomized to undergo sartorius transposition or not. All patients received perioperative antibiotics, DVT prophylaxis, and closed suction surgical site drainage. Outcomes assessed include wound cellulitis, wound breakdown, lymphocyst formation, lymphedema, and/or rehospitalization. Cohorts were compared using Fisher's exact test. Baseline characteristics were compared using Student's t test or Fischer's exact test as appropriate. Logistic regression was used to assess the impact of sartorius transposition, after adjusting for other factors. From June 1996 to December 2002, 61 patients underwent 99 inguinal-femoral lymphadenectomies, 28 with sartorius transposition, and 33 without. The mean (SD) age for controls and patients undergoing sartorius transposition was 63.5 (15.2) and 73.8 (13.7) years, respectively (P < 0.05). There were no statistically significant differences in BSA, tobacco use, co-morbid medical conditions, past surgical history, medication use, size of incision, duration of surgery, number of positive lymph nodes, pathologic stage, pathologic grade, pre- or postoperative hemoglobin, or length of hospitalization. There were no statistically significant differences in the incidence of wound cellulitis, wound breakdown, lymphedema, or rehospitalization. The incidence of lymphocyst formation was increased in the sartorius transposition group. After adjusting for age, however, the groups appeared similar. Sartorius transposition after inguinal-femoral lymphadenectomy does not reduce postoperative wound morbidity.",
keywords = "Inguinal-femoral, Lymphadenectomy, Sartorius transposition",
author = "Judson, {Patricia L.} and Jonson, {Amy L.} and Paley, {Pamela J.} and Bliss, {Robin L.} and Murray, {Karuna P.} and Downs, {Levi S.} and Boente, {Matthew P.} and Argenta, {Peter A.} and Carson, {Linda F.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1016/j.ygyno.2004.07.022",
language = "English (US)",
volume = "95",
pages = "226--230",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy

AU - Judson, Patricia L.

AU - Jonson, Amy L.

AU - Paley, Pamela J.

AU - Bliss, Robin L.

AU - Murray, Karuna P.

AU - Downs, Levi S.

AU - Boente, Matthew P.

AU - Argenta, Peter A.

AU - Carson, Linda F.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Based on the reduced morbidity seen in our retrospective study, we undertook a prospective, randomized trial to determine whether transposition of the sartorius muscle improves post-operative morbidity in women with squamous cell carcinoma of the vulva undergoing inguinal-femoral lymphadenectomy. Patients with squamous carcinoma of the vulva requiring inguinal-femoral lymphadenectomy were randomized to undergo sartorius transposition or not. All patients received perioperative antibiotics, DVT prophylaxis, and closed suction surgical site drainage. Outcomes assessed include wound cellulitis, wound breakdown, lymphocyst formation, lymphedema, and/or rehospitalization. Cohorts were compared using Fisher's exact test. Baseline characteristics were compared using Student's t test or Fischer's exact test as appropriate. Logistic regression was used to assess the impact of sartorius transposition, after adjusting for other factors. From June 1996 to December 2002, 61 patients underwent 99 inguinal-femoral lymphadenectomies, 28 with sartorius transposition, and 33 without. The mean (SD) age for controls and patients undergoing sartorius transposition was 63.5 (15.2) and 73.8 (13.7) years, respectively (P < 0.05). There were no statistically significant differences in BSA, tobacco use, co-morbid medical conditions, past surgical history, medication use, size of incision, duration of surgery, number of positive lymph nodes, pathologic stage, pathologic grade, pre- or postoperative hemoglobin, or length of hospitalization. There were no statistically significant differences in the incidence of wound cellulitis, wound breakdown, lymphedema, or rehospitalization. The incidence of lymphocyst formation was increased in the sartorius transposition group. After adjusting for age, however, the groups appeared similar. Sartorius transposition after inguinal-femoral lymphadenectomy does not reduce postoperative wound morbidity.

AB - Based on the reduced morbidity seen in our retrospective study, we undertook a prospective, randomized trial to determine whether transposition of the sartorius muscle improves post-operative morbidity in women with squamous cell carcinoma of the vulva undergoing inguinal-femoral lymphadenectomy. Patients with squamous carcinoma of the vulva requiring inguinal-femoral lymphadenectomy were randomized to undergo sartorius transposition or not. All patients received perioperative antibiotics, DVT prophylaxis, and closed suction surgical site drainage. Outcomes assessed include wound cellulitis, wound breakdown, lymphocyst formation, lymphedema, and/or rehospitalization. Cohorts were compared using Fisher's exact test. Baseline characteristics were compared using Student's t test or Fischer's exact test as appropriate. Logistic regression was used to assess the impact of sartorius transposition, after adjusting for other factors. From June 1996 to December 2002, 61 patients underwent 99 inguinal-femoral lymphadenectomies, 28 with sartorius transposition, and 33 without. The mean (SD) age for controls and patients undergoing sartorius transposition was 63.5 (15.2) and 73.8 (13.7) years, respectively (P < 0.05). There were no statistically significant differences in BSA, tobacco use, co-morbid medical conditions, past surgical history, medication use, size of incision, duration of surgery, number of positive lymph nodes, pathologic stage, pathologic grade, pre- or postoperative hemoglobin, or length of hospitalization. There were no statistically significant differences in the incidence of wound cellulitis, wound breakdown, lymphedema, or rehospitalization. The incidence of lymphocyst formation was increased in the sartorius transposition group. After adjusting for age, however, the groups appeared similar. Sartorius transposition after inguinal-femoral lymphadenectomy does not reduce postoperative wound morbidity.

KW - Inguinal-femoral

KW - Lymphadenectomy

KW - Sartorius transposition

UR - http://www.scopus.com/inward/record.url?scp=4644259502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644259502&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.07.022

DO - 10.1016/j.ygyno.2004.07.022

M3 - Article

C2 - 15385136

AN - SCOPUS:4644259502

VL - 95

SP - 226

EP - 230

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -